1,030 results on '"Tagawa, Scott T."'
Search Results
2. The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis
3. Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy
4. Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial
5. PSMA PET improves characterization of dural-based intracranial lesions in patients with metastatic prostate cancer
6. Barriers and facilitators of the application of precision medicine to the genitourinary cancer care pathway: Perspective from a low- and middle- income country in sub-Saharan Africa
7. Systematic Review and Meta-analysis of Minimally Invasive Procedures for Surgical Inguinal Nodal Staging in Penile Carcinoma
8. Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)
9. Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer
10. Management of Lymph Node–positive Penile Cancer: A Systematic Review
11. Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial
12. Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial
13. A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors
14. Antibody-drug conjugates for urothelial carcinoma
15. Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
16. European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update
17. Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting
18. Management of Fibroblast Growth Factor Inhibitor Treatment–emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
19. PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer
20. Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy.
21. ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug.
22. SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer.
23. Final results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).
24. Ischemic stroke with cancer: Hematologic and embolic biomarkers and clinical outcomes
25. What Is the Most Effective Management of the Primary Tumor in Men with Invasive Penile Cancer: A Systematic Review of the Available Treatment Options and Their Outcomes
26. Adherence to Guideline-Recommended Cancer Screening in Stroke Survivors: A Nationwide Analysis
27. Correlation analyses of radiographic progression‐free survival with clinical and health‐related quality of life outcomes in metastatic castration‐resistant prostate cancer: Analysis of the phase 3 VISION trial.
28. TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.
29. Ischemic Stroke with Comorbid Cancer Has Specific miRNA‐mRNA Networks in Blood That Vary by Ischemic Stroke Mechanism.
30. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
31. Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma
32. Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
33. Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
34. Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1
35. Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2
36. FIGURE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
37. Data from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
38. Supplementary Tables S1-S10 from Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation
39. Data from Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation
40. Supplementary Figures S1-S7 from Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation
41. Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond
42. Use of Biosimilar Medications in Oncology
43. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
44. Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3
45. FIGURE 2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
46. Supplementary Table S4 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
47. Supplementary Figure S2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
48. TABLE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
49. TABLE 3 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
50. TABLE 4 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.